甘李药业(603087) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached CNY 930.11 million, an increase of 37.61% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was CNY 208.36 million, reflecting a growth of 57.47% year-over-year[4] - The basic earnings per share for Q3 2024 was CNY 0.35, up 45.83% from the previous year[4] - Domestic sales revenue in Q3 2024 was CNY 680 million, a 22.25% increase year-over-year, driven by rising prices of formulation products[10] - International sales revenue for Q3 2024 was CNY 117 million, showing a significant growth of 72.10% compared to the same period last year[10] - The net profit attributable to shareholders for the year-to-date period reached CNY 507.27 million, a substantial increase of 90.36% year-over-year[4] - Total revenue for the first three quarters of 2024 reached ¥2,245,006,087.12, a 17.8% increase from ¥1,905,670,877.67 in the same period of 2023[19] - Net profit for the first three quarters of 2024 was ¥507,265,199.52, compared to ¥266,475,847.45 in 2023, representing a 90.2% increase[19] Assets and Liabilities - The total assets at the end of Q3 2024 amounted to CNY 12.22 billion, a 4.32% increase from the end of the previous year[4] - Total assets as of September 30, 2024, amounted to ¥12,221,620,665.54, up from ¥11,715,023,471.80 at the end of 2023[18] - Current assets totaled ¥6,488,421,495.55, an increase from ¥6,175,749,710.54 in the previous year[18] - The total liabilities as of September 30, 2024, were ¥1,014,756,330.68, compared to ¥972,517,044.16 at the end of 2023[18] - The company's total equity reached ¥11,206,864,334.86, an increase from ¥10,742,506,427.64 at the end of 2023[18] Cash Flow - The company reported a net cash flow from operating activities of CNY 465.34 million for the year-to-date period, reflecting an increase due to higher cash receipts from sales[8] - In the first three quarters of 2024, the company generated cash inflows from operating activities amounting to CNY 2,482,539,982.35, a significant increase from CNY 1,772,951,330.30 in the same period of 2023, representing a growth of approximately 40.0%[21] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 465,340,293.85, compared to a negative cash flow of CNY -76,956,258.80 in the first three quarters of 2023, indicating a turnaround in operational performance[21] - The company reported cash and cash equivalents at the end of the third quarter of 2024 amounting to CNY 272,242,587.07, down from CNY 393,508,471.53 at the end of the same period in 2023[23] - The total cash outflow from financing activities in the first three quarters of 2024 was CNY 137,407,531.31, compared to CNY 3,503,968.02 in the same period of 2023, indicating a significant increase in financing activities[23] - The net cash flow from financing activities for the first three quarters of 2024 was CNY 1,914,068.69, recovering from a negative cash flow of CNY -3,503,968.02 in the same period of 2023[23] Research and Development - Research and development expenses for the first three quarters of 2024 were ¥403,442,931.89, compared to ¥369,945,734.16 in 2023, indicating an increase of 9.0%[19] Sales and Procurement - The company expects continued growth in revenue driven by successful bidding in national drug procurement and price increases in insulin products[9] - The company secured a first-year agreement volume of 46.86 million insulin units in the latest round of centralized procurement, representing a 32.6% increase compared to the previous procurement[11] - International sales revenue reached 242 million RMB in the first three quarters of 2024, marking a 37.63% year-on-year growth, with Q3 sales revenue increasing by 72.10% compared to the same period last year[11] - The company's franchise service revenue amounted to 135 million RMB in the first three quarters of 2024, a 34.49% increase year-on-year, primarily due to increased milestone revenue recognition[11]